文献速递系统性红斑狼疮

异常BMI对SLE患者52周治疗后不良健康相关生活质量结局的贡献

Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

基于BLISS-52和BLISS-76两项试验(n=1684)的SLE患者数据,分析异常BMI与52周标准治疗联合belimumab或安慰剂后不良HRQoL结局的关联。结果显示超重和肥胖与不良SF-36躯体成分摘要及FACIT-F评分相关,低体重与不良SF-36心理成分摘要相关,belimumab对不良总体健康和严重疲劳有独立保护作用。

要点

  • 超重和肥胖增加SLE患者52周治疗后不良躯体HRQoL和严重疲劳风险。
  • 低体重与不良心理HRQoL相关,校正混杂因素后仍显著。
  • belimumab独立降低不良总体健康和严重疲劳风险。

核心结论

  • 超重和肥胖贡献于SLE患者治疗干预后不良躯体和心理HRQoL结局,低体重贡献于不良心理HRQoL结局。
  • belimumab对不良总体健康和严重疲劳具有保护作用。

研究设计与样本

  • 分析BLISS-52(NCT00424476)和BLISS-76(NCT00410384)试验数据,共1684例SLE患者。
  • 不良HRQoL定义为SF-36评分≤年龄和性别匹配的美国人群第5百分位,FACIT-F评分<30。
  • 使用Pearson χ2检验比较BMI组,多变量logistic回归评估独立性。

主要发现

  • 超重(BMI≥25 kg/m2)患者第52周不良SF-36躯体成分摘要OR为1.8(95%CI 1.4, 2.3;P<0.001),FACIT-F OR为1.3(95%CI 1.1, 1.6;P=0.010)。
  • 肥胖(BMI≥30 kg/m2)患者第52周不良SF-36躯体成分摘要OR为2.4(95%CI 1.8, 3.2;P<0.001),FACIT-F OR为1.5(95%CI 1.2, 2.0;P=0.002)。
  • 低体重与不良SF-36心理成分摘要相关,校正性别、种族、年龄、病程、疾病活动度、器官损害和研究期间泼尼松剂量后OR为2.1(95%CI 1.2, 3.6;P=0.007)。
  • 标准治疗联合belimumab独立保护不良SF-36总体健康(OR 0.8;95%CI 0.6, 1.0;P=0.025)和FACIT-F<30(OR 0.8;95%CI 0.6, 1.0;P=0.018)。

关键数值与推荐

  • 超重定义为BMI≥25 kg/m2,肥胖定义为BMI≥30 kg/m2。
  • 不良HRQoL的SF-36阈值:≤年龄和性别匹配美国人群第5百分位;FACIT-F阈值:<30。

临床怎么用

  • 对SLE患者应关注BMI,超重/肥胖者需关注躯体HRQoL和疲劳,低体重者需关注心理HRQoL。
  • belimumab治疗可能有助于改善总体健康和严重疲劳相关结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate whether abnormal BMI is associated with adverse health-related quality of life (HRQoL) outcome, including severe fatigue, after 52 weeks of standard therapy plus belimumab or placebo in patients with SLE. METHODS: We analysed data from the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials (n = 1684). Adverse HRQoL was defined as SF-36 scores ≤ the fifth percentile in age- and sex-matched US population-based subjects, and FACIT-F scores <30. We compared BMI groups using the Pearson's χ2 test, and assessed independence with multivariable logistic regression analysis. RESULTS: Overweight (BMI ≥25 kg/m2) and obese (BMI ≥30 kg/m2) patients showed increased likelihood to exhibit adverse SF-36 physical component summary (OR: 1.8; 95% CI: 1.4, 2.3; P <0.001 and OR: 2.4; 95% CI: 1.8, 3.2; P <0.001, respectively) and FACIT-F (OR: 1.3; 95% CI: 1.1, 1.6; P = 0.010 and OR: 1.5; 95% CI: 1.2, 2.0; P = 0.002, respectively) scores at week 52. Underweight was associated with adverse SF-36 mental component summary scores, also after adjustment for sex, ancestry, age, disease duration, disease activity, organ damage and prednisone dose during the study period (OR: 2.1; 95% CI: 1.2, 3.6; P = 0.007). Addition of belimumab to standard therapy independently protected against adverse SF-36 general health (OR: 0.8; 95% CI: 0.6, 1.0; P = 0.025) and FACIT-F < 30 (OR: 0.8; 95% CI: 0.6, 1.0; P = 0.018). CONCLUSION: Overweight and obesity contributed to adverse physical and mental HRQoL outcomes after therapeutic intervention in SLE patients, and underweight contributed to adverse mental HRQoL outcome. A protective effect of belimumab against adverse general health and severe fatigue was implicated.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Borg A, Gomez A, Cederlund A, et al. Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE. Rheumatology (Oxford). 2021. PMID: 33404659. doi:10.1093/rheumatology/keaa909

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。